No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

BACKGROUND: The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potent...

Full description

Saved in:
Bibliographic Details
Main Authors: Vangsted, Annette J, Søeby, Karen, Klausen, Tobias W, Abildgaard, Niels, Andersen, Niels F, Gimsing, Peter, Gregersen, Henrik, Vogel, Ulla, Werge, Thomas, Rasmussen, Henrik B
Format: Artigo
Language:Inglês
Published: BioMed Central 2010
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2922196/
https://ncbi.nlm.nih.gov/pubmed/20684753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-404
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items